World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
72
Citations
23725
World Ranking
19784
National Ranking
9850

Overview

James W. Mier is affiliated with Beth Israel Deaconess Medical Center in the United States. Their research primarily focuses on medicine, with a significant emphasis on oncology, molecular biology, obstetrics and gynecology, cancer research, and reproductive medicine.

Their scientific work covers various topics related to cancer treatment and molecular biology, including:

  • Endometrial and cervical cancer treatments
  • Cancer immunotherapy and biomarkers
  • Cancer-related molecular pathways
  • Ovarian cancer diagnosis and treatment
  • Angiogenesis and VEGF in cancer
  • Prostate cancer treatment and research
  • CAR-T cell therapy research

James W. Mier has contributed to several publications, primarily in the following venues:

  • Journal of Clinical Oncology
  • Molecular Cancer

Selected recent papers by Mier include:

  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer, 2020, Journal of Clinical Oncology
  • Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC), 2020, Journal of Clinical Oncology
  • Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial, 2020, Journal of Clinical Oncology
  • Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells, 2021, Molecular Cancer
  • Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma, 2021, Molecular Cancer

Their frequent collaborators include:

  • Vicky Makker
  • Matthew H. Taylor
  • Carol Aghajanian
  • Ana Oaknin
  • Allen Lee Cohn

Best Publications

  • Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55

    Herbert Tilg;Elizabeth Trehu;Michael B. Atkins;Charles A. Dinarello

  • Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion

    Arnold H. Zea;Paulo C. Rodriguez;Michael B. Atkins;Claudia Hernandez

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

  • IL-6 and APPs: anti-inflammatory and immunosuppressive mediators.

    Herbert Tilg;Charles A. Dinarello;James W. Mier

  • Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis

    Arthur Kaser;Gerald Brandacher;Wolfgang Steurer;Susanne Kaser;Susanne Kaser

  • Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

    Michael B. Atkins;Michael J. Robertson;Michael Gordon;Michael T. Lotze

  • Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth

    George D. Kamphaus;Pablo C. Colorado;David J. Panka;Helmut Hopfer

  • Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

    Jeffrey J. Wallin;Johanna C. Bendell;Roel Funke;Mario Sznol

  • Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

    Michael Atkins;Meredith Regan;David McDermott;James Mier

  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.

    David Avigan;Baldev Vasir;Jianlin Gong;Virginia Borges

  • Multiple biological activities of human recombinant interleukin 1.

    C A Dinarello;J G Cannon;J W Mier;H A Bernheim

  • Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells: A Phase II Clinical Trial

    Fisher Ri;Coltman Ca;Doroshow Jh;Rayner Aa

  • Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor

    Joseph E. Gootenberg;Francis W. Ruscetti;James W. Mier;Adi Gazdar

  • Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

    Vicky Makker;Drew Rasco;Nicholas J Vogelzang;Marcia S Brose

  • Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

    Michael B. Atkins;James W. Mier;David R. Parkinson;Jody A. Gould

  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

    Vicky Makker;Matthew H. Taylor;Carol Aghajanian;Ana Oaknin

  • Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

    Jared A. Gollob;James W. Mier;Korina Veenstra;David F. McDermott

  • Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells.

    David J. Panka;Toshiaki Mano;Toshimitsu Suhara;Kenneth Walsh

  • T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor

    Bernard J. Poiesz;Francis W. Ruscetti;James W. Mier;Andrea M. Woods

  • Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media

    James W. Mier;Robert C. Gallo

Frequent Co-Authors

Michael B. Atkins
Michael B. Atkins Georgetown University
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Charles A. Dinarello
Charles A. Dinarello University of Colorado Anschutz Medical Campus
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Kim Margolin
Kim Margolin City Of Hope National Medical Center
Ryan J. Sullivan
Ryan J. Sullivan Harvard University
Richard I. Fisher
Richard I. Fisher Fox Chase Cancer Center
David C. Alsop
David C. Alsop Beth Israel Deaconess Medical Center
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical studies in the USA opens up a range of allied health careers beyond the traditional MD route. Many students are now choosing flexible online pathways to accelerate or specialize their medical education. For example, easiest online dnp programs appeal to nurses who want to advance into leadership or specialist roles without leaving their current jobs.

If you’re looking for a quicker entry into healthcare, exploring fast track medical programs such as online LPN courses can help you join the workforce sooner. For those interested in mental health, the fastest psych np program options allow registered nurses to specialize rapidly and start making a difference in behavioral health care.

Healthcare administration is another growing field. The best online mha programs offer affordable, flexible education for those who want to lead health organizations or manage hospital systems. Choosing the right online degree can help you reach your career goals in medicine and healthcare more efficiently.

Best Scientists Citing James W. Mier

Trending Scientists

Recently Published Articles